Business
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3
ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused ...
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, on November 3, 2025, at 4:15 p.m. ET.","length":356,"tagName":"p"},{"type":"text","content":"During the exclusive event, featuring Connect Biopharma's CEO, Barry Quart, PharmD, attendees will gain insights into how Connect Biopharma is advancing next-generation biologic therapies designed to transform treatment for severe respiratory diseases. The Company's lead candidate, rademikibart, is a differentiated, next-generation monoclonal antibody targeting IL-4Rα with the potential to set a new standard in the treatment of acute and chronic asthma and COPD. Backed by strong global Phase 2 data showing rapid improvement in lung function and a favorable safety profile, rademikibart is now being advanced through Phase 2 "Seabreeze STAT" studies in acute exacerbations of asthma and COPD, with topline data expected in the first half of 2026. Dr. Quart will discuss the Company's clear regulatory path to Phase 3 trials, robust financial position with cash runway into 2027, and large commercial opportunity exceeding $5 billion in combined peak sales potential across asthma and COPD, positioning Connect Biopharma as a catalyst-driven growth story in immunology and respiratory medicine.","length":1120,"tagName":"p"},{"type":"text","content":"A live question and answer session will follow the presentation.","length":64,"tagName":"p"},{"type":"text","content":"To register for the free webinar, please visit: https://www.redchip.com/webinar/CNTB/81394173620","length":96,"tagName":"p"},{"type":"text","content":"Questions can be pre-submitted to [email protected] or online during the live event.","length":83,"tagName":"p"},{"type":"text","content":"About Rademikibart","length":18,"tagName":"p"},{"type":"text","content":"Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). We believe that by binding with IL-4Rα, rademikibart can block the functions of IL-4 and IL-13 effectively, thereb...